drug_type
RELEVANT_DRUG
intervention_type
Biological (monoclonal antibody)
drug_description
Fully human IgG1 monoclonal antibody (VAY736) that binds and blocks the BAFF receptor (BAFF-R/TNFRSF13C) on B cells, inhibiting BAFF-mediated survival signaling and inducing B-cell depletion via ADCC (and potentially complement), thereby reducing pathogenic autoantibody production.
nci_thesaurus_concept_id
C116788
nci_thesaurus_definition
A fully human combinatorial antibody library (HuCAL)-derived monoclonal antibody targeting the B-cell-activating factor receptor (BAFF-R), with potential anti-inflammatory and antineoplastic activities. Upon administration, ianalumab targets and binds to BAFF-R, which inhibits both BAFF/BAFF-R interaction and BAFF-R-mediated signaling. This may decrease cell growth in tumor cells expressing BAFF-R. BAFF-R, also known as tumor necrosis factor receptor superfamily member 13C, is overexpressed in certain tumor cell types and autoimmune diseases. In cancer cells, BAFF-R plays a key role in B-cell proliferation and survival. VAY736 was developed using HuCAL technology.
drug_mesh_term
ianalumab
drug_category
INHIBITORY ANTIBODY
drug_class
Inhibitor
drug_delivery_route
Not specified
drug_mechanism_of_action
Fully human IgG1 monoclonal antibody against BAFF receptor (TNFRSF13C) that blocks BAFF–BAFF-R binding and downstream survival signaling in B cells, and engages Fc effector functions (ADCC ± complement) to deplete B cells, thereby reducing BAFF-dependent B-cell survival and pathogenic autoantibody production.
drug_name
Ianalumab
nct_id_drug_ref
NCT05885555